K36 Ther­a­peu­tics rais­es $70M in Se­ries B to fund mul­ti­ple myelo­ma re­search

K36 Ther­a­peu­tics raised $70 mil­lion to help fund an on­go­ing clin­i­cal tri­al for its lead and on­ly can­di­date, an oral mul­ti­ple myelo­ma treat­ment.

The Cam­bridge, MA-based biotech on Wednes­day re­vealed the new cash in­flux. The Se­ries B was led by VC Nex­tech In­vest and in­clud­ed Bris­tol My­ers Squibb and all pre­vi­ous in­vestors, such as Eight Roads Ven­tures, At­las Ven­ture and F-Prime Cap­i­tal.

The biotech broke out of stealth back in De­cem­ber 2021, with $30 mil­lion from a Se­ries A that closed ear­li­er that year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER